Organogenesis falls after joint disease therapy fails to meet late-stage study goal

** Shares of Organogenesis ORGO.O fall 11.1% to $4.16 in extended trade

** Company says its experimental therapy, ReNu, did not meet the main goal in its second late-stage trial for knee osteoarthritis, despite showing numerical improvement in pain reduction

** Knee osteoarthritis is a degenerative joint condition where the protective cartilage in the knee wears away, leading to pain, stiffness, swelling and a grinding or crackling sensation with movement

** As of last close, stock up 46.2% YTD